TCg㈭ËɅWԊpżҭ

SciClone Pharmaceuticals International, Ltd.

ZADAXIN Thymosin Alpha 1

ƢE⺭θЭ᭎ڲҭV@

  • Ͷ (pԐ)

Z A D A X I NTM iU_Vj`V㴰AѰt@P @ thymosin alpha 1 (thymalfasin) Aǭa^ɭ̭ASDԿ死ɜ񭁭ǭiB̭P㮭C^[tFٰ㭮gٽխgpҭBιAb^ɪA䖶^ExɈAFڔAHIV/AIDS魂θЭڲҭԿ歈ԱFAҭCtѰGUAa^ɰN`Կ٭نpBEBѰXڲҭʭa^ɪAb^ɭɫƛƢE⺭Tl鶋򭏪AɈd쭅W᭎ѡʭB

ZADAXINAB䌭ҭکRz᭎zѰA`V㴰AѰt@1ـȭA`ƛaRفЭsEmjEٓp᭎筀AuVXeȭBuƧ@\ɳ歸ZADAXINAθڒθlËȶDԿݶB


S

`V㴰AѰt@PSL^ǭ٭ЪAͶͶԱAlA٭AɆުAa^b^,ɜusSڲҪAeڒɈQƍl鶋`V㴰AѰt@P̭ڗ᭻AAٓpЪAA`V㴰AѰt@PݪAC^[tFٰ㭉w@gٽխpAٓpܭЭ魎ʭխBԱlKƯ^800{^ҭAŸLQͶԗFխB


ǭa^ɭ

a^ɭ筃AWAθԩɫƛBZADAXINAAѰ[`AJ{WAAΪANEF[gALVRA~}[AyѪ[AtBɰsAVK|[ѪAxlYGŪAxgiAǭa^A갶N`نɝ䳭FҭASciCloneȭιeέF\⺭io[Ԫ[AuѰlCAh~jJaΪAChAChlVAAC^ɰAAɯΪAŰIXA}Ԫ[VAA}Ѱ^ApLX^AXɰŰJA^CAAŰuږAMA LѰMXaΪAEYxLX^aAアザバイジャンAジョージアAマルダイブスjBZADAXINAWAAC^[tFٰ㭻ŸNOFҭöŭa^AsFҭiBAWAAê[ٰbpAέ^ꭃAZADAXINǭa^ɭ̭ԿIʭҭBȭvż\B

a^Ա
ͶԱ ZADAXIN Rg٪[
@ξQiK 10/12 (83%) 2/8 (25%)
@ξRiK 12/50 (24%) 6/49 (12%)
Ίp@ξRiK 19/51 (37%) 13/52 (25%)
v 41/113 (36%) 21/109 (19%)

AȭιԱZADAXINLԿǭmFҭBǭa^̭`V㴰AѰt@PC^[tFٰLԿǭr᭎C^ɰAԱA~UԋAC^[tFٰ㭁̭ڗaЭﭏﭵ뭵A`V㴰AѰt@P̭ڗ񭃭Կ死αBέAᭁǭa^̭Ët𞭻FC^[tFٰ㭮ҭD˶᭎AFھ㲭Bawŕŕwɚż{ҭƦθԱAZADAXINkね̭ڗǭa^47%AҭAZADAXINC^[tFٰٽ̭ڗ61%ALԿ㲭B


ǭb^ɭ

b^ɭ̭AZADAXINA٠ڲҭBÐFC^[tFٰ㭮gٽխpAف٭Կ㲭A٠ԱSAZADAXINC^[tFٰٽ̭C^[tFٰP㮭̭D死\BC^ɰAs魒`V㴰AѰt@PC^[tFٰٽԱAgٽխɜ筀Կ死α᭎ۭB

فѧέԱAUڭC^[tFٰ㭮ٽZADAXINgp᭎AC^[tFٰ̭ڗٽꭩ16.6%D㲭魢䊭תAٽ̭ڗ񭃭41.9%AӭD(ż\Qj



C^ɰAŧ18ףּ{ҭԱA`V㴰AѰt@PC^[tFٰٽ̭ݭPNڗ40%A~ԋUڭAαϭB

Rb^Աf[^فѧꭁA`V㴰AѰt@PC^[tFٰ㭃@Aǭb^̭筀ɰbgʭ_tBSf[^ݶW᭎Aż\ϭ歏AC^[tFٰ̭{ҭ񭃭ꭩ22.2%Կ死筀魢䊭תAZADAXINC^[tFٰٽ@44.7%٭oB



v

٠Ѻ歃ɔǪASciCloneAF孃ͶԱKvΪXȭٽխԱݪAf[^ϭs\魎ΪXAKvo^ڏαǭ쭆խB٠isѵż\歏B

i δnþ Kp ѵ
ZADAXIN
`VEAѰt@P
AѰ[`AChAuѰlCAJ{WAAΪANEF[gA}Ԫ[VAA~}[ApLX^AyѪ[AtBɰsAVK|[ѪAXɰŰJAxlYGŪAxgiA^CAŰIXA}Ѱ^Ao[Ԫ[Ah~jJaΪAChlVAALVRAAŰuږAMAEYxLX^aΪALѰMXaΪAアザバイジャンAジョージアAマルダイブス ǭa^ s
AѰ[`AyѪ[A~}[AtBɰsALVRAxlYGŪAh~jJaΪALVRAVK|[ѪAEYxLX^a AXɰŰJA}Ѱ^A pLX^Aマルダイブス ǭb^ s
tBɰsa Ɉ s
AѰ[`AΪALVRA~}[AɯΪAC^ɰAAh~jJaΪAEYxLX^a A^CA tBɰsa F
oOŰfVAuŰWѪA`ɪARٰrAALvٰXAGWvgA٪`ACXŰGѪA԰omAlp[ѪAj[W[ŰhAΊpA^CAgѰR ǭa^ \
Ίp ǭa^ ξRiKɨ
ǭb^ ξRiK
{ ǭa^ ξRiK
{ ǭb^ ξQiK
ŢB Ɉ ξQiK

ɎѮEFuTCgݭЭҭ


©1991-2002 SciClone Pharmaceuticals International Ltd. All Rights Reserved Worldwide.
Site built by ATG